Your browser doesn't support javascript.
loading
Homologous Recombination Deficiency: Concepts, Definitions, and Assays.
Stewart, Mark D; Merino Vega, Diana; Arend, Rebecca C; Baden, Jonathan F; Barbash, Olena; Beaubier, Nike; Collins, Grace; French, Tim; Ghahramani, Negar; Hinson, Patsy; Jelinic, Petar; Marton, Matthew J; McGregor, Kimberly; Parsons, Jerod; Ramamurthy, Lakshman; Sausen, Mark; Sokol, Ethan S; Stenzinger, Albrecht; Stires, Hillary; Timms, Kirsten M; Turco, Diana; Wang, Iris; Williams, J Andrew; Wong-Ho, Elaine; Allen, Jeff.
Afiliação
  • Stewart MD; Friends of Cancer Research, Washington, DC, USA.
  • Merino Vega D; Friends of Cancer Research, Washington, DC, USA.
  • Arend RC; Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingam, AL, USA.
  • Baden JF; Translational Medicine, Bristol Myers Squibb, New York, NY, USA.
  • Barbash O; Oncology Experimental Medicine Unit, GlaxoSmithKline, Philadelphia, PA, USA.
  • Beaubier N; Tempus Labs, Inc., Chicago, IL, USA.
  • Collins G; Friends of Cancer Research, Washington, DC, USA.
  • French T; Global Medical Affairs, Diagnostics, AstraZeneca, Cambridge, UK.
  • Ghahramani N; Molecular Genetic Pathology Regional Laboratory, SCPMG Regional Reference Laboratories, Los Angeles, CA, USA.
  • Hinson P; Independent Cancer Research Patient Advocate, Charlotte, NC, USA.
  • Jelinic P; Early Clinical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Marton MJ; Early Clinical Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.
  • McGregor K; Cancer Genomics Research Group, Foundation Medicine, Cambridge, MA, USA.
  • Parsons J; Tempus Labs, Inc., Chicago, IL, USA.
  • Ramamurthy L; Global Regulatory Affairs, GlaxoSmithKline, Washington, DC, USA.
  • Sausen M; Translational Medicine, Bristol Myers Squibb, New York, NY, USA.
  • Sokol ES; Cancer Genomics Research Group, Foundation Medicine, Cambridge, MA, USA.
  • Stenzinger A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Stires H; Friends of Cancer Research, Washington, DC, USA.
  • Timms KM; Myriad Genetics, Inc., Salt Lake City, UT, USA.
  • Turco D; Myriad Genetics, Inc., Salt Lake City, UT, USA.
  • Wang I; Global Precision Medicine, Novartis Pharmaceuticals Corporation, New York, NY, USA.
  • Williams JA; Precision Medicine & Biosamples, AstraZeneca, Cambridge, UK.
  • Wong-Ho E; Clinical Sequencing Division, Thermo Fisher Scientific, San Francisco, CA, USA.
  • Allen J; Friends of Cancer Research, Washington, DC, USA.
Oncologist ; 27(3): 167-174, 2022 03 11.
Article em En | MEDLINE | ID: mdl-35274707
BACKGROUND: Homologous recombination deficiency (HRD) is a phenotype that is characterized by the inability of a cell to effectively repair DNA double-strand breaks using the homologous recombination repair (HRR) pathway. Loss-of-function genes involved in this pathway can sensitize tumors to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapy, which target the destruction of cancer cells by working in concert with HRD through synthetic lethality. However, to identify patients with these tumors, it is vital to understand how to best measure homologous repair (HR) status and to characterize the level of alignment in these measurements across different diagnostic platforms. A key current challenge is that there is no standardized method to define, measure, and report HR status using diagnostics in the clinical setting. METHODS: Friends of Cancer Research convened a consortium of project partners from key healthcare sectors to address concerns about the lack of consistency in the way HRD is defined and methods for measuring HR status. RESULTS: This publication provides findings from the group's discussions that identified opportunities to align the definition of HRD and the parameters that contribute to the determination of HR status. The consortium proposed recommendations and best practices to benefit the broader cancer community. CONCLUSION: Overall, this publication provides additional perspectives for scientist, physician, laboratory, and patient communities to contextualize the definition of HRD and various platforms that are used to measure HRD in tumors.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Inibidores de Poli(ADP-Ribose) Polimerases Tipo de estudo: Guideline / Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Inibidores de Poli(ADP-Ribose) Polimerases Tipo de estudo: Guideline / Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article